JP3868494B2 - オピオイドアンタゴニストおよびそれらの使用方法 - Google Patents

オピオイドアンタゴニストおよびそれらの使用方法 Download PDF

Info

Publication number
JP3868494B2
JP3868494B2 JP50950797A JP50950797A JP3868494B2 JP 3868494 B2 JP3868494 B2 JP 3868494B2 JP 50950797 A JP50950797 A JP 50950797A JP 50950797 A JP50950797 A JP 50950797A JP 3868494 B2 JP3868494 B2 JP 3868494B2
Authority
JP
Japan
Prior art keywords
peptide
opioid
receptor
ofq
mammalian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP50950797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001520634A5 (enExample
JP2001520634A (ja
Inventor
グリセル，ジュディス・イー
モーギル，ジェフリー・エス
グランディ，デーヴィッド・ケイ
ブンゾウ，ジェームズ・アール
スィヴェリ，オリヴィエ
ラインシェイド，ライナー・クラウス
ノトハッカー，ハンス−ペーター
モンスマ，フレデリック・ジェームズ
Original Assignee
オレゴン・ヘルス・サイエンスィズ・ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/514,451 external-priority patent/US5837809A/en
Application filed by オレゴン・ヘルス・サイエンスィズ・ユニバーシティ filed Critical オレゴン・ヘルス・サイエンスィズ・ユニバーシティ
Publication of JP2001520634A publication Critical patent/JP2001520634A/ja
Publication of JP2001520634A5 publication Critical patent/JP2001520634A5/ja
Application granted granted Critical
Publication of JP3868494B2 publication Critical patent/JP3868494B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP50950797A 1995-08-11 1996-08-12 オピオイドアンタゴニストおよびそれらの使用方法 Expired - Lifetime JP3868494B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/514,451 1995-08-11
US08/514,451 US5837809A (en) 1995-08-11 1995-08-11 Mammalian opioid receptor ligand and uses
US08/553,058 1995-11-03
US08/553,058 US5821219A (en) 1995-08-11 1995-11-03 Opioid antagonists and methods of their use
PCT/US1996/013305 WO1997007212A1 (en) 1995-08-11 1996-08-12 Opioid antagonists and methods of their use

Publications (3)

Publication Number Publication Date
JP2001520634A JP2001520634A (ja) 2001-10-30
JP2001520634A5 JP2001520634A5 (enExample) 2004-09-09
JP3868494B2 true JP3868494B2 (ja) 2007-01-17

Family

ID=27058205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50950797A Expired - Lifetime JP3868494B2 (ja) 1995-08-11 1996-08-12 オピオイドアンタゴニストおよびそれらの使用方法

Country Status (8)

Country Link
US (1) US5821219A (enExample)
EP (1) EP0843726B1 (enExample)
JP (1) JP3868494B2 (enExample)
AT (1) ATE323160T1 (enExample)
AU (1) AU728001B2 (enExample)
CA (1) CA2229126A1 (enExample)
DE (1) DE69636037D1 (enExample)
WO (1) WO1997007212A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
EP0813065A3 (en) * 1996-06-13 1998-07-22 F. Hoffmann-La Roche Ag Modulation of LC132 (opioid-like) receptor function
AU8333998A (en) * 1997-07-15 1999-02-10 Novo Nordisk A/S New use of nociceptin
WO1999003880A1 (en) * 1997-07-15 1999-01-28 Novo Nordisk A/S Nociceptin analogues
US5929035A (en) * 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
US6582457B2 (en) * 2001-02-15 2003-06-24 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US6849449B2 (en) * 2001-03-01 2005-02-01 Regents Of The University Of Michigan Orphanin FQ receptor nucleic acids
EP1406629A1 (en) * 2001-07-02 2004-04-14 Omeros Corporation Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
US7049287B2 (en) * 2001-10-09 2006-05-23 Synvax, Inc. Nociceptin-based analgesics
WO2003093294A2 (en) * 2002-04-29 2003-11-13 Euro-Celtique S.A. Conformationally constrained peptides that bind the orl-1 receptor
AU2003257111A1 (en) * 2002-08-02 2004-02-23 Incyte Corporation Extracellular messengers
MXPA05002622A (es) 2002-09-09 2005-09-08 Johnson & Johnson Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano.
ES2528631T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
US7173010B2 (en) * 2003-05-19 2007-02-06 Regents Of The University Of Michigan Orphanin FQ receptor
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
EP1890696A4 (en) 2005-06-02 2010-05-05 Janssen Pharmaceutica Nv Suitable as new ORL-1 receptor modulators are 3-pyrolytic indolyl derivatives
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US8703948B2 (en) 2006-11-28 2014-04-22 Janssen Pharmaceutica Nv Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
PA8774201A1 (es) 2007-03-29 2009-06-23 Progenics Pharm Inc Antagonista del receptor
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
JP5490677B2 (ja) 2007-04-09 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのｏｒｌ−１受容体リガンドとしての１，３，８−三置換−１，３，８−トリアザ−スピロ［４．５］デカン−４−オン誘導体
WO2008142454A1 (en) 2007-05-22 2008-11-27 Prosidion Limited Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders
US8063247B2 (en) 2007-09-07 2011-11-22 Prosidion Limited Bicyclic aryl and heteroaryl receptor modulators
CN101959892B (zh) 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
RU2492482C1 (ru) * 2012-10-08 2013-09-10 Игорь Петрович Папышев Способ диагностики причины смерти от интоксикации наркотическими веществами группы опиатов

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582820A (en) * 1982-12-23 1986-04-15 Research Corporation Orally administered biologically active peptides and proteins
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5017689A (en) * 1989-07-06 1991-05-21 Arizona Technology Development Corporation Dynorphin analogs specific for kappa opioid receptors
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US6235496B1 (en) * 1993-03-08 2001-05-22 Advanced Research & Technology Institute Nucleic acid encoding mammalian mu opioid receptor

Also Published As

Publication number Publication date
WO1997007212A1 (en) 1997-02-27
JP2001520634A (ja) 2001-10-30
AU728001B2 (en) 2001-01-04
EP0843726A1 (en) 1998-05-27
DE69636037D1 (de) 2006-05-24
EP0843726B1 (en) 2006-04-12
CA2229126A1 (en) 1997-02-27
AU6776996A (en) 1997-03-12
ATE323160T1 (de) 2006-04-15
US5821219A (en) 1998-10-13

Similar Documents

Publication Publication Date Title
JP3868494B2 (ja) オピオイドアンタゴニストおよびそれらの使用方法
US5837809A (en) Mammalian opioid receptor ligand and uses
Andriamampandry et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator γ‐hydroxybutyrate
JP3273792B2 (ja) Ｎｍｄａレセプターのアロステリックモジュレーター
US6429289B1 (en) Class BI and CI scavenger receptors
US20010010919A1 (en) Opioid antagonists and methods of their use
JP2002514055A (ja) ガラニンｇａｌｒ３受容体をコードするｄｎａおよびその使用
US7863416B2 (en) Nociceptin-based analgesics
SK8752000A3 (en) Novel g protein-coupled receptor
CA2422288A1 (en) Novel mammalian receptor genes and uses
JP2010046088A (ja) 新規なぺプチド類
EP0700438B1 (en) Opioid receptors: compositions and methods
JP6000245B2 (ja) 鎮痛作用とａｓｉｃチャンネルを阻害する新規ペプチド
JP4191796B2 (ja) 拮抗剤または作動剤として、ヒトｏｒｌ１受容体に結合できることが知られていない化合物を回収する方法
JPH08502902A (ja) ヒト５−ｈｔ▲下２▼レセプター
US6406866B1 (en) Method of screening of a compound for binding to MSOR
JP4512273B2 (ja) 新規なぺプチド類
US7381542B2 (en) Nucleic acids encoding a biogenic amine receptor
US20090081227A1 (en) Human and mammalian stem cell-derived neuron survival factors
JP2000078994A (ja) 新規７―トランスメンブラン受容体をコ―ドしているｃＤＮＡクロ―ンＨＮＦＤＹ２０
Erdei Biochemical, functional and pharmacological characterization of novel bifunctional peptide ligands and nociceptin variants
JP2002507385A (ja) ヒトの５−ｈｔ４セロトニン作動性受容体のスプライシングバリアント、及び、特にスクリーニングのためのその利用
WO2004009630A1 (en) Regulation of human serotonin receptor
EP1568770A2 (en) Pharmaceutical use of compounds which bind to a mammalian "trace amine" receptor
US20030104572A1 (en) Nucleic acid molecules encoding kappa3, opioid receptors, receptors encoded thereby, and uses thereof

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20061011

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091020

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101020

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111020

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121020

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131020

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term